Data / Drug companies / Liraglutide
Liraglutide: 11 companies and 22 products in the FDA NDC directory
Liraglutide is listed in the FDA National Drug Code Directory by 11 companies, with 22 products in commercial distribution. 15 of the products (68.2%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, solution; injection, and the newest product started marketing on April 25, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 11
- Products
- 22
- Generic (ANDA) products
- 15 (68.2%)
- Application numbers
- 10
- Routes
- Subcutaneous
- Brand names
- Victoza, Saxenda
- openFDA record search
- api.fda.gov
Companies that list liraglutide
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 5 | injection; injection, solution | New drug applications (NDA) | January 22, 2026 |
| Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | 3 | injection, solution | Generic drugs (ANDA) | December 24, 2024 |
| Biocon Pharma Inc. | 2 | injection, solution; injection | Generic drugs (ANDA) | April 25, 2026 |
| Cipla USA Inc. | 2 | injection, solution | Generic drugs (ANDA) | February 25, 2026 |
| Novo Nordisk | 2 | injection, solution; injection | New drug applications (NDA) | December 31, 2014 |
| Orbicular Pharmaceutical Technologies Private Limited | 2 | injection, solution | Generic drugs (ANDA) | February 26, 2026 |
| Teva Pharmaceuticals, Inc. | 2 | injection, solution; injection | Generic drugs (ANDA) | August 28, 2025 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection | Generic drugs (ANDA) | December 24, 2024 |
| Lupin Pharmaceuticals, Inc. | 1 | injection | Generic drugs (ANDA) | October 2, 2025 |
| Meitheal Pharmaceuticals Inc. | 1 | injection | Generic drugs (ANDA) | April 2, 2025 |
| NorthStar RxLLC | 1 | injection | Generic drugs (ANDA) | March 1, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 12 | 54.5% |
| Injection | 10 | 45.5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 15 | 68.2% |
| New drug applications (NDA) | 5 | 22.7% |
| Authorized generics (NDA) | 2 | 9.1% |
Pharmacologic classes
| Class | Products |
|---|---|
| GLP-1 Receptor Agonist | 22 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.